Last updated on July 2008

Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Follicular Lymphoma
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Signature of the written informed consent by the subject or his/her legal
    representative before initiation of any trial specific procedure.
    Patients older than 18.
    Histologic diagnosis of CD20+, grade 1-3a follicular lymphoma as per the WHO
    High-risk patients according to FLIPI before initiation of induction chemotherapy.
    Stage II-IV prior to initiation of induction treatment, or any stage in patients with
    grade 3 follicular lymphoma.
    Complete or partial response to the induction scheme.
    ECOG scale performance status 0 - 2.
    Life expectancy greater than 3 months.
    In women of childbearing age, use of a reliable contraceptive method.
    A suitable bone marrow reserve:
    Lower than 25% Bone marrow infiltration by lymphoma.
    Hb 10 g/dL. PMN leukocytes 1,500 cel/mm3, platelets 100,000/mm3
    Suitable hepatic, renal and cardiac function:
    creatinine <2,5 x UNL (upper normality limit).
    bilirubin or ALT/AST < 2,5 x UNL

You may not be eligible for this study if the following are true:

  • Patients with no objective clinical response to induction chemotherapy.
    > 25% bone marrow infiltration following induction chemotherapy.
    Platelets < 100,000 before radioimmunotherapy.
    Severe and/or uncontrolled concomitant disease:
    Hepatic, renal, cardiovascular, neurological or metabolic disease.
    Cardiac failure, ischemic cardiopathy, ischemic cardiopathy with a history of
    myocardial infarction or angor, or major ventricular arrhythmia.
    Positive regarding HBV, HCV, HIV.
    Active acute or chronic infection.
    Social, psychic or geographic disability to satisfy any of the treatment schemes.
    Pregnant and/or breastfeeding women, or adult patients of childbearing age who are
    not using a safe birth control device throughout the study treatment and at least 12
    months thereafter.
    Known or suspected hypersensitivity, or confirmed or suspected adverse reaction to
    the study drugs and other related compounds (Rituximab, Ibritumomab tiuxetan, a
    history of sensitivity to murine proteins, dexametasone, cyclophosphamide and other
    anthracyclines, cytarabine).

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.